Fundamental Analysis of Keros Therapeutics Inc - Growth / Value Index


KROS - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Very Poor Score of 5.00
   Price to Book Ratio of 1102.94 suggesting that it is very expensive
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -2175.29 -9.75 13.69 %
Price to Book 988.81 4.49 5.34 % 3.04
Price to Sales 1490182 9883.39 16608.36 %
Enterprise Value to EBITDA Multiple -8.05 -7.64 12.18 %


KROS - Profitability Highlights

Profitability Analysis

   Excellent QoQ /QoQ FY EPS growth
   Tsr Profitability Index - Very Poor Score of 5.00
   Piotroski F Score - Very Poor Value of 2.0
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
   EPS decline for last four quarters
   Negative Net Margin MRQ
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity -45.46 -46.05 -22.05 % -9.50
Return On Asset -41.68 -41.35 -21.17 % -8.87
Net Profit Margin -68505.13 -101319.21 -19258.08 % -51944.58
Operating Profit Margin -75707.26 -110954.30 -19231.70 % -58413.25
EBITDA Margin -72253.42 -100779.47 -19279.92 % -58413.25


Highlights
Market Cap1691.25 M
Enterprise Value1361.11 M
Price/Book TTM988.81
Outstanding Share36083.90 K
Float/ Outstanding Share85.76%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score2.00
Altman Z Score25.08
Sloan Ratio-0.077
Peter Lynch Fair Value0


KROS - Growth Highlights

Growth Analysis

   YoY Net Margin Jump by 19258.08%
   Steady increase in Total Assets for last 3 Years
   Tsr Growth Index - Very Poor Score of 10.09
   Annual sales in last 3 years is trending down
   Companies' sales dropped by 99.25 % from last year
   Operating Cash Flow decreasing for last 3 year
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 234000 99.25 % 41.96 %
Gross Profit -311000.00 109.35 % 41.96 %
EBITDA -169073.00 K 46.32 % 21.22 %
Net Profit -160302.00 K 46.15 % 7.13 %
EPS -0.0215 15.86 % NA


KROS - Stability Highlights

Stability Analysis

   Altman Z Score of 28.17 suggests good Stability
   Cash ratio of 13.59
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of 0
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.0030 84.45 % 0.0023
Cash Ratio 13.59 -19.43 %
Quick Ratio 13.67 -21.06 % 24.74
Shareholders Equity 89.78 -0.718 %
Debt to EBITDA -0.0066 -50.96 %


Historical Valuation Ratios of Keros Therapeutics Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Keros Therapeutics Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Keros Therapeutics Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Keros Therapeutics Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)